Skip to content
New: 100+ more US companies, including the big banks, plus insider trades from SEC filings

Health Care · NYSE: ZTS

Zoetis: how the business works

Zoetis makes medicines, vaccines and tests for pets and farm animals, and had revenue of $9.47 billion in FY2025.

By · Checked against filings: . Editorial policy. Corrections

Follow Zoetis

Email me when Zoetis's page is updated after earnings.

We'll send a confirmation email first. See our privacy policy.

Zoetis Inc. · Parsippany, New Jersey · Founded 2012

Updated for Q3 FY2026 · checked

Revenue, FY2025
$9.47B
Net income, FY2025
$2.67B
Revenue from pet products, FY2025
69.6%
Employees, Dec 31, 2025
About 14,500
Incorporated
2012

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Zoetis in 5 points

  1. 1 · What it sells

    Zoetis sells medicines, vaccines and diagnostic tests for animals, with revenue of $9.47 billion in FY2025; parasiticides were the largest category at $2.34 billion.

    More: what it sells

  2. 2 · Who pays it

    In FY2025, pet products brought in 69.6% of Zoetis's revenue, farm-animal products 29.2% and contract manufacturing and human health 1.2%, mostly through vets and vet distributors.

    More: who pays it

  3. 3 · What it keeps from $100

    Of every $100 that came in during FY2025, Zoetis kept $28.1 as net income after $7.2 of income tax and $2.3 of interest; items outside operations added only a net $36 million, and EBITDAOperating profit before wear-and-tear charges (depreciation and amortization). As a margin: per $100 of sales. (operating profit before depreciation and amortization) was $4.03 billion.

    More: what it keeps from $100

  4. 4 · Where the operating profit comes from

    The United States segment earned $3,438 million of FY2025 segment earnings on $5,097 million of revenue, and International $2,264 million on $4,254 million.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    US companion animal revenue fell 8% in Q3 FY2026, while livestock revenue rose to $797 million from $746 million.

    More: the one thing to watch

Sources: From Zoetis's FY2025 10-K and the Q3 FY2026 earnings release · checked

01Where the money goes · FY2025

Where does $100 of Zoetis' money go?

Of every $100 that came in (revenue plus other income), this is where it went.

Zoetis · FY2025

Receipt for every $100

Where $100 of Zoetis' money went in FY2025
Making the products$28.1
Selling and administration$25.0
Research and development$7.4
Amortization and restructuring$1.9
Interest$2.3
Income tax$7.2
Kept as net income$28.1
Total$100

Each line = amount ÷ total money in × 100. Lines may not add to exactly $100 because of rounding.

How this is worked out

Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (revenue of $9.47 billion plus $36 million of net other income): each line = line ÷ $9.50 billion × 100.

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report earnings, explained in 5 points.

No tips. Unsubscribe anytime.

We'll send a confirmation email. See our privacy policy.

02The business in one line

What does Zoetis do?

Vets, distributors and farmers pay Zoetis for animal medicines, vaccines and tests; making and selling them takes most of the money. In FY2025, $28.1 of every $100 was left as net income.

  • Pet products brought in 69.6% of FY2025 revenue and farm-animal products 29.2%, mostly sold through vets and vet distributors.
  • Making the products took $28.1 of every $100 and selling and administration $25.0, with $7.4 on research and $7.2 on income tax.

03Who pays it

Who pays Zoetis?

  • Pet owners, through vets

    69.6%

    of revenue

    Medicines, vaccines and tests for dogs, cats and horses, usually bought by vets or vet distributors and sold on to owners. $6.59 billion in FY2025.

  • Livestock farmers

    29.2%

    of revenue

    Products for cattle, swine, poultry, fish and sheep, sold to vets, farmers, distributors and retailers. $2.76 billion in FY2025.

  • Contract manufacturing and human health

    1.2%

    of revenue

    Making products for other companies, plus some human health products. $116 million in FY2025.

  • Pet owners, through vets69.6%
  • Livestock farmers29.2%
  • Contract manufacturing and human health1.2%

Customer concentration

The largest customer, a US veterinary distributor that Zoetis does not name, bought about 16% of FY2025 revenue. Zoetis gives no top-5 or top-10 customer share.

Largest customer
16%

04How it makes money

How does Zoetis make money?

Patented pet medicines carry high gross margins, which pay for the sales teams and research.

In FY2025 the US segment kept 83.5% of its sales as gross margin and International 69.2%. That covered $2.38 billion of selling and administration and $698 million of research, and still left $28.2 of net income per $100 of revenue.

Net income per $100 of revenue

$26.2$28.2

FY2021 to FY2025

  1. Research finds a new medicine, such as an antibody shot for dog arthritis pain.
  2. Patents and approvals keep direct copies away for years.
  3. Sales teams sell it to vets, who prescribe it to pet owners.
  4. High gross margins turn the sales into profit and cash.
  5. The cash pays for more research, dividends and share buybacks.

↺ Step 5 feeds back into step 1.

05Business segments · FY2025

Which businesses make up Zoetis?

  • United States

    53.8%

    Sales in the US, 83% of them for pets in FY2025. The profit figure is Zoetis's own segment earnings measure.

    Revenue $5.1B ($5,097M) · Operating profit $3.4B ($3,438M)

  • International

    44.9%

    Sales in all other countries, 56% for pets and 44% for farm animals in FY2025.

    Revenue $4.3B ($4,254M) · Operating profit $2.3B ($2,264M)

  • Contract manufacturing and human health

    1.2%

    Making products for other companies, plus human health products; Zoetis reports it outside its two segments.

    Revenue $116M

How the mix changed

  • United States
  • International
  • Contract manufacturing and human health

Revenue by segment, FY2021 to FY2025.

US$

See the numbers
How the mix changed (US$)
YearUnited StatesInternationalContract manufacturing and human health
FY2021$4.0B$3.7B$82M
FY2022$4.3B$3.7B$86M
FY2023$4.6B$3.9B$78M
FY2024$5.1B$4.1B$80M
FY2025$5.1B$4.3B$116M

06The numbers · Consolidated · US$

How has Zoetis done?

Revenue

$9.5BFY2025

Revenue rose every year, from $7.78 billion in FY2021 to $9.47 billion in FY2025, and was $2.39 billion in Q3 FY2026 against a recast $2.42 billion a year earlier.

US$

See the numbers
Revenue (US$)
PeriodRevenue (US$)
FY2021$7.8B
FY2022$8.1B
FY2023$8.5B
FY2024$9.3B
FY2025$9.5B
Q1 FY2024$2.2B
Q2 FY2024$2.4B
Q3 FY2024$2.4B
Q4 FY2024$2.3B
Q1 FY2025$2.2B
Q2 FY2025$2.5B
Q3 FY2025$2.4B
Q4 FY2025$2.4B
Q1 FY2026$2.3B
Q2 FY2026$2.5B
Q3 FY2026$2.4B

Net income

$2.7BFY2025

Net income rose every year to $2.67 billion in FY2025. Q1 to Q3 FY2025 are recast because non-US subsidiaries stopped reporting one month late from Jan 1, 2026; the years and Q4 rows are as first filed.

US$

See the numbers
Net income (US$)
PeriodNet income (US$)EPS ($)
FY2021$2.0B$4.27
FY2022$2.1B$4.49
FY2023$2.3B$5.07
FY2024$2.5B$5.47
FY2025$2.7B$6.02
Q1 FY2024$599M$1.31
Q2 FY2024$624M$1.37
Q3 FY2024$682M$1.50
Q4 FY2024$581M$1.29
Q1 FY2025$602M$1.34
Q2 FY2025$726M$1.63
Q3 FY2025$721M$1.63
Q4 FY2025$603M$1.37
Q1 FY2026$601M$1.42
Q2 FY2026$691M$1.65
Q3 FY2026$591M$1.44

Net income for every $100 of revenue

$28.2FY2025

Zoetis kept between $26.2 and $28.2 of net income per $100 of revenue in each year from FY2021 to FY2025.

Net margin: $ of net income per $100 of revenue

See the numbers
Net income for every $100 of revenue (Net margin: $ of net income per $100 of revenue)
YearNet marginEBITDA margin
FY202126.2%41.3%
FY202226.2%41.9%
FY202327.4%41.0%
FY202426.9%41.4%
FY202528.2%42.6%

Free cash flow

$2.3BFY2025

Free cash flow was $2.28 billion in FY2025, close to $2.30 billion in FY2024 and up from $1.74 billion in FY2021.

US$ · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (US$ · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY2021$2.2B$477M$1.7B
FY2022$1.9B$586M$1.3B
FY2023$2.4B$732M$1.6B
FY2024$3.0B$655M$2.3B
FY2025$2.9B$621M$2.3B
See all yearly numbers
Zoetis annual financials, FY2021–FY2025, US$
YearRevenueEBITDANet incomeEPS ($)Operating cashCapexFree cash
FY2021$7.8B$3.2B$2.0B$4.27$2.2B$477M$1.7B
FY2022$8.1B$3.4B$2.1B$4.49$1.9B$586M$1.3B
FY2023$8.5B$3.5B$2.3B$5.07$2.4B$732M$1.6B
FY2024$9.3B$3.8B$2.5B$5.47$3.0B$655M$2.3B
FY2025$9.5B$4.0B$2.7B$6.02$2.9B$621M$2.3B

EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Fiscal year ends Dec 31. Net income is the share belonging to the company's owners.

Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares

07Who runs it

Who runs Zoetis, and did they deliver?

  • Kristin C. Peck

    Chief Executive Officer · since 2020

    CEO since Jan 2020 and a director since Oct 2019.

  • Wetteny Joseph

    Chief Financial Officer (as named in the FY2025 10-K) · since 2021

    CFO since Jun 2021 per the FY2025 10-K. The Q3 FY2026 10-Q refers to a transition of the CFO in Aug 2026.

  • Jamie Brannan

    EVP, Chief Commercial Officer · since 2024

    In the role since Nov 2024.

  • Kevin Esch

    EVP and President, Research and Development · since 2026

    In the role since Jan 2026.

  • Michael B. McCallister

    Independent Board Chair · since 2013

    Chair since Jun 2013; former CEO of Humana. All directors except the CEO are independent.

What they said, and what happened

1 delivered · 2 too early to tell

  1. Said on Feb 13, 2025

    In Feb 2025 Zoetis guided to FY2025 revenue of $9.225 to $9.375 billion; in Nov 2025 it revised the range to $9.400 to $9.475 billion.

    What happened

    FY2025 revenue was $9.467 billion, inside the revised range and above the first one.

    Delivered
  2. Said on Feb 12, 2026

    On Feb 12, 2026 Zoetis guided to FY2026 revenue of $9.825 to $10.025 billion, with 3% to 5% organic operational growth.

    What happened

    Lowered to $9.680 to $9.960 billion on May 7, 2026 and $9.120 to $9.320 billion on Aug 6, 2026, then narrowed to $9.220 to $9.320 billion on Nov 5, 2026. The full-year result comes with Q4 FY2026.

    Too early to tell
  3. Said on Feb 12, 2026

    On Feb 12, 2026 Zoetis guided to FY2026 adjusted diluted EPS of $7.00 to $7.10.

    What happened

    The range was $6.25 to $6.35 on Nov 5, 2026, after a cut to $6.15 to $6.25 on Aug 6, 2026.

    Too early to tell

08What could go wrong

What could go wrong for Zoetis?

  • Concentration

    A few products earn a large share of revenue

    Simparica, Apoquel, Cytopoint, Librela and the ceftiofur line brought in about 42% of FY2025 revenue; the top ten about 57%.

    Watch Dermatology and parasiticide sales each quarter

  • Competition

    Weaker demand and more competition in US pet products

    US companion animal revenue fell 8% in Q3 FY2026. Zoetis cited price-sensitive pet owners, competition in dermatology and generic competition, and cut its FY2026 revenue guidance.

    Watch US companion animal revenue growth

  • Concentration

    One distributor buys about a sixth of sales

    The largest customer, an unnamed US veterinary distributor, bought about 16% of FY2025 revenue.

    Watch The largest customer's share in the FY2026 10-K

  • Debt

    More debt after buybacks

    Debt rose to $9.05 billion at Sep 30, 2026 from $6.57 billion at Dec 31, 2024, while shareholders' equity fell to $3.30 billion. $750 million of notes are due in 2027 and $2.0 billion of convertible notes in 2029.

    Watch Net debt and the Moody's and S&P ratings

  • Legal

    Securities class action

    A class action filed in May 2026 alleges misleading statements about demand for four key products. Zoetis says it has substantial defenses; damages are not specified.

    Watch Court rulings on the amended complaint

  • Currency

    Currency changes

    About 42% of FY2025 revenue came in currencies other than the US dollar, mainly the euro, Brazilian real, Australian dollar, British pound, Canadian dollar and Chinese renminbi.

    Watch Currency effects in each earnings release

09Supporters vs. critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Revenue rose every year, from $7.78 billion in FY2021 to $9.47 billion in FY2025, and net income rose every year to $2.67 billion.
  • Zoetis kept between $26.2 and $28.2 of net income per $100 of revenue in each year from FY2021 to FY2025.
  • In Q3 FY2026, livestock revenue was $797 million against $746 million and diagnostics $128 million against $112 million.
  • Dividends declared per share rose from $1.08 in FY2021 to $2.03 in FY2025, and buybacks were $3.24 billion in FY2025.
  • Zoetis held more than 5,500 granted patents and 1,600 pending applications in over 50 countries, per its FY2025 10-K.

What critics point to

  • US companion animal revenue fell 8% in Q3 FY2026; Zoetis cited price-sensitive pet owners, competition in dermatology and generic competition.
  • Zoetis guided on Feb 12, 2026 to FY2026 revenue of $9.825 to $10.025 billion; on Nov 5, 2026 the range was $9.220 to $9.320 billion.
  • Dermatology sales were $1.15 billion in the first nine months of FY2026, against a recast $1.32 billion a year earlier.
  • Debt rose to $9.05 billion at Sep 30, 2026 from $6.57 billion at Dec 31, 2024, while shareholders' equity fell to $3.30 billion from $4.77 billion.
  • Five product lines brought in about 42% of FY2025 revenue, and one unnamed distributor bought about 16%.

10What to watch next

What should you watch next at Zoetis?

Next event

Q4 FY2026 results

Date not announced yet.

  • Results against the FY2026 range

    In its Nov 5, 2026 earnings release, Zoetis said it expects FY2026 revenue of $9.220 to $9.320 billion and adjusted diluted EPS of $6.25 to $6.35. FY2025 revenue was $9.47 billion.

  • US pet product sales

    US companion animal revenue fell 8% in Q3 FY2026. Pet products were 69.6% of FY2025 revenue.

  • Dermatology against the new pain shots

    Dermatology sales were $1.15 billion in the first nine months of FY2026, against a recast $1.32 billion. In Q3 FY2026 the longer-acting Lenivia launched in Great Britain and Portela won Swiss approval.

  • Debt and buybacks

    $750 million of notes due 2027 are now current, and $770 million was left under the buyback program at Sep 30, 2026. Net debt was $7.52 billion on that date.

  • The class action

    A securities class action filed on May 27, 2026 alleges misleading statements about demand for four key products; an amended complaint followed on Oct 23, 2026. Zoetis says it has substantial defenses.

11Key facts

Key facts about Zoetis

What does Zoetis do?
Zoetis Inc. makes medicines, vaccines and diagnostic tests for animals. It sold about 300 product lines in more than 100 countries in FY2025, for dogs, cats, horses, cattle, swine, poultry, fish and sheep.
How does Zoetis make money?
Zoetis earns money by selling animal health products. Of its $9.47 billion of FY2025 revenue, parasiticides (flea, tick and worm treatments) brought in $2.34 billion, vaccines $1.96 billion and dermatology medicines $1.75 billion.
Who are Zoetis's customers?
Zoetis sells mainly to vets, vet distributors and livestock farmers. Pet products were 69.6% of Zoetis's FY2025 revenue and farm-animal products 29.2%; its largest customer, an unnamed US veterinary distributor, bought about 16%.
How big is Zoetis?
Zoetis had revenue of $9.47 billion and net income of $2.67 billion in FY2025 (the year ended Dec 31, 2025). It had about 14,500 employees at Dec 31, 2025.
Where does Zoetis sell?
The United States brought in 53.8% of Zoetis's FY2025 revenue and all other countries 44.9%. Brazil was the largest country outside the US, at 4.2% of FY2025 revenue.
How did Zoetis do in Q3 FY2026?
Zoetis had revenue of $2.39 billion in Q3 FY2026 (Jul to Sep 2026), against a recast $2.42 billion in Q3 FY2025. Net income was $591 million, against a recast $721 million a year earlier.
How much debt does Zoetis have?
Zoetis had total debt of $9.05 billion at Sep 30, 2026, against cash and short-term investments of $1.53 billion. That leaves net debt of $7.52 billion (Cityfort calculation from the Q3 FY2026 10-Q).
Does Zoetis pay dividends and buy back shares?
Zoetis declared dividends of $2.03 per share for FY2025, up from $1.08 for FY2021. It spent $3.24 billion buying back its own shares in FY2025.
Who owns Zoetis?
Zoetis has one class of stock with one vote per share, and no holder controls it. Its 2026 proxy statementThe yearly filing about shareholder votes, the board and executive pay. Learn more lists The Vanguard Group with 11.36% and BlackRock with 8.68% (from a Jan 2024 filing). Directors and executive officers held about 0.2% at Mar 20, 2026 (Cityfort calculation from the 2026 proxy statement).
Where did Zoetis come from?
Zoetis was a business unit of Pfizer before it was incorporated in Delaware in July 2012. Zoetis shares began trading on the NYSE as ZTS on Feb 1, 2013.

Terms on this page

Each explains the term in plain English, with the same number from other companies on Cityfort.

Go deeper

More detail from the same filings. Open any section.

12What it sells

12What it sells

What does Zoetis sell?

Zoetis makes medicines, vaccines and diagnostic tests for animals. Pets (dogs, cats, horses) brought in $6.59 billion of FY2025 revenue and farm animals $2.76 billion.
  • Parasiticides

    Treatments against fleas, ticks and worms, such as the monthly Simparica Trio chew for dogs. $2.34 billion of FY2025 revenue, the largest category.

  • Vaccines

    Vaccines for pets and farm animals. $1.96 billion of FY2025 revenue.

  • Dermatology

    Itch and allergy medicines for dogs, mainly the Apoquel tablet and the Cytopoint injection. $1.75 billion in FY2025.

  • Anti-infectives

    Antibiotics, mostly for farm animals, such as Draxxin for cattle and swine and the ceftiofur line. $1.04 billion in FY2025.

  • Pain and sedation

    Includes Librela for dogs and Solensia for cats, antibody shots for arthritis pain. $840 million in FY2025.

  • Diagnostics

    Tests and analyzers that vets use to find out what is wrong with an animal. $434 million in FY2025.

What it does

  • Does: Sells about 300 product lines in more than 100 countries.
  • Does: Covers eight species: dogs, cats, horses, cattle, swine, poultry, fish and sheep.
  • Does: Runs 21 of its own manufacturing sites in 10 countries and uses over 90 outside contract makers.

What it does not do

  • Does not: Does not mainly sell to pet owners directly: it sells to vets or vet distributors, and vets then sell to owners.
  • Does not: Does not make human medicines at scale: contract manufacturing and human health were $116 million, about 1% of FY2025 revenue.
  • Does not: No longer sells medicated feed additives: it sold that portfolio to Phibro Animal Health on Oct 31, 2024.
13How the money flows

13How the money flows · FY2025

How does money flow through Zoetis?

Money in

  • Revenue$9.5B
  • Other income, net$36M

The company

Zoetis

$9.5B came in

Money out

  • Making the products$2.7B
  • Selling and administration$2.4B
  • Research and development$698M
  • Amortization and restructuring$179M
  • Interest$222M
  • Income tax$687M
  • Net income$2.7B
  1. Vets, distributors and farmers paid Zoetis $9.47 billion of revenue in FY2025.
  2. Making the products cost $2.67 billion, leaving $6.80 billion of gross profit.
  3. Selling and administration took $2.38 billion and research $698 million; amortization and restructuring took $179 million.
  4. Interest cost $222 million, while other items added a net $36 million.
  5. Income tax took $687 million, and $2.67 billion was left as net income.
14What it needs to run

14What it needs to run

What does Zoetis need to run?

  • Factories and contract makers

    21 manufacturing sites in 10 countries at Dec 31, 2025, plus over 90 outside contract manufacturers. Many products are made at a single site.

  • Research

    Research and development cost $698 million in FY2025, about $7.40 of every $100 of revenue. The main research center is in Kalamazoo, Michigan.

  • Patents

    More than 5,500 granted patents and 1,600 pending applications in over 50 countries protect its products.

  • People

    About 14,500 employees at Dec 31, 2025: about 6,800 in the US and 7,700 elsewhere.

15Where it sells

15Where it sells · FY2025

Where does Zoetis sell?

  • United States53.8%
  • Brazil4.2%
  • Australia3.5%
  • United Kingdom3.4%
  • Canada3.1%
  • Germany2.5%
  • China2.4%
  • All other countries25.9%
  • Contract manufacturing and human health1.2%
16Competitors and what protects it

16Competitors and what protects it

Who does Zoetis compete with?

Zoetis says in its FY2025 10-K that it is the largest animal health business by revenue, competing on new products, quality, price, service and promotion.
  • Boehringer Ingelheim Animal Health

    The animal health division of Boehringer Ingelheim; Zoetis names it first among its primary competitors in medicines, vaccines and diagnostics.

  • Merck Animal Health

    NYSE: MRK

    The animal health division of Merck & Co.; named by Zoetis as a primary competitor.

  • Elanco Animal Health

    Named by Zoetis as a primary competitor in animal health medicines and vaccines.

  • IDEXX Laboratories

    NASDAQ: IDXX

    Named by Zoetis as a primary competitor; the overlap is in diagnostics, where Zoetis had $434 million of FY2025 revenue.

What protects the business

Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.

  • Reach and range4 of 5

    About 300 product lines sold in more than 100 countries, across eight species, made in 21 own sites.

  • Patents3 of 5

    More than 5,500 granted patents and 1,600 pending applications in over 50 countries; the patents on Draxxin and the active-ingredient patents on Excede have expired.

  • Brand loyalty with vets3 of 5

    Zoetis says in its FY2025 10-K that it believes brand loyalty often continues after patents end, because quality and safety matter to vets and owners.

  • Research spending3 of 5

    $698 million of research and development in FY2025, up from $508 million in FY2021.

Weak spot

Dog itch medicines under pressure

Dermatology sales (Apoquel, Cytopoint) were $1.15 billion in the first nine months of FY2026, down from a recast $1.32 billion a year earlier; Zoetis cited competitive pressure in dermatology.

17Where growth could come from

17Where growth could come from

Where could Zoetis' growth come from?

In its Q3 FY2026 earnings release (Nov 5, 2026), Zoetis said it expects FY2026 revenue of $9.220 to $9.320 billion and adjusted diluted EPS of $6.25 to $6.35. On Feb 12, 2026 it had guided to $9.825 to $10.025 billion of revenue.
Management statement, Nov 5, 2026. Reported as a statement, not our forecast.
  • Parasiticides (Simparica Trio)

    Working

    $1.86B in 9M FY2026 vs $1.79B

    Flea, tick and worm products grew in the first nine months of FY2026 against recast figures for the year before. Simparica Trio got a US emergency use authorization for New World screwworm in dogs in Q3 FY2026.

    Status: Working, on track against what the company said.

  • Dermatology (Apoquel, Cytopoint)

    Behind

    $1.15B in 9M FY2026 vs $1.32B

    Sales fell in each of Q1, Q2 and Q3 FY2026 against the recast quarters of FY2025. Zoetis cited price-sensitive pet owners and competitive pressure in dermatology.

    Status: Behind, behind the company's own plan.

  • Arthritis pain shots (Librela, Solensia, Lenivia, Portela)

    Early

    Pain and sedation category: $200M in Q3 FY2026, flat

    US sales of Librela and Solensia fell in Q4 FY2025. Longer-acting Lenivia (dogs) and Portela (cats) won their first approvals in 2025; in Q3 FY2026 Lenivia launched in Great Britain and Portela won Swiss approval.

    Status: Early, too early to judge.

  • Livestock and diagnostics

    Working

    Livestock $797M in Q3 FY2026 vs $746M

    Farm-animal sales and diagnostics ($128 million vs $112 million) grew in Q3 FY2026; the CEO said they partly offset pressure in pet products.

    Status: Working, on track against what the company said.

  • International markets

    Working

    9M FY2026 revenue +9% reported

    International revenue was $3.44 billion in the first nine months of FY2026, against a recast $3.14 billion; Zoetis puts operational growth at 5%.

    Status: Working, on track against what the company said.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

18The company's own measures (non-GAAP)

18The company's own measures · FY2025 and Q3 FY2026

What do Zoetis' own measures show?

Adjusted (non-GAAP) figures are the company's own measures, shown next to the nearest GAAP figure. The rest of this page uses GAAP figures. Zoetis publishes no adjusted EBITDA.
  • Official (GAAP): Net income, FY2025

    $2.7B

    Company's own measure: Adjusted net income, FY2025

    $2.8B

    Zoetis leaves out purchase accounting adjustments, acquisition and divestiture costs and certain significant items, $174 million net in FY2025.

  • Official (GAAP): Diluted EPS, FY2025

    $6.02

    Company's own measure: Adjusted diluted EPS, FY2025

    $6.41

    Same exclusions as adjusted net income, per diluted share.

  • Official (GAAP): Reported revenue growth, FY2025

    2.0%

    Company's own measure: Organic operational revenue growth, FY2025

    6%

    Removes currency changes and the effect of acquisitions and divestitures, such as the medicated feed additive sale in Oct 2024.

  • Official (GAAP): Net income, Q3 FY2026

    $591M

    Company's own measure: Adjusted net income, Q3 FY2026

    $720M

    The $129 million gap includes a $78 million write-down of research projects bought with PetMedix in 2023, and restructuring costs.

  • Official (GAAP): Diluted EPS, Q3 FY2026

    $1.44

    Company's own measure: Adjusted diluted EPS, Q3 FY2026

    $1.75

    Same exclusions as adjusted net income, per diluted share.

These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (GAAP) figure.

Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out

19Financial strength and debt

19Financial strength · Sep 30, 2026

How much debt does Zoetis have?

Net debt was $7.52 billion at Sep 30, 2026, about 1.9 times FY2025 EBITDA of $4.03 billion (Cityfort calculation from the Q3 FY2026 10-Q and the FY2025 10-K).
  • Total debt$9.0B
  • Cash and investments$1.5B
  • Net debt (debt minus cash)$7.5B
  • Net worth (shareholders' money)$3.3B
Debt to equity
2.74×
$ of debt for every $1 of shareholders' money
  • Total debt of $9.05 billion is senior notes at carrying value: $750 million of 3.000% notes due 2027 is now current and $8.30 billion is long-term. Lease liabilities are left out.
  • Cash of $1.33 billion plus $200 million of short-term investments is $1.53 billion, so net debt is $7.52 billion (Cityfort calculation from the Q3 FY2026 10-Q).
  • Debt rose from $6.57 billion at Dec 31, 2024 to $9.04 billion at Dec 31, 2025. In 2025 Zoetis sold $1.85 billion of senior notes in August and $2.0 billion of 0.25% convertible notes due 2029 in December, and repaid $1.35 billion of notes.
  • A $1.25 billion revolving credit line was undrawn at Sep 30, 2026, with no commercial paper outstanding.
  • Shareholders' equity was $3.30 billion at Sep 30, 2026, against $4.77 billion at Dec 31, 2024; treasury stock (shares bought back) was $12.35 billion at cost.
20Who owns it

20Who owns it · ownership as of Mar 20, 2026

Who owns Zoetis?

Each share has one vote and no holder controls Zoetis. The 22 directors and executive officers together held 912,848 shares, deferred units and exercisable options, about 0.2% of the 420.6 million shares at Mar 20, 2026 (Cityfort calculation from the 2026 proxy statement).
Officers and directors (as a group), shares
0.2%
Share classes
Zoetis share classes: shares outstanding (millions) and votes per share
ClassShares (millions)Votes per shareHeld by% of shares% of votesTraded
Common stock (407.49 million shares at Sep 30, 2026 (Q3 FY2026 10-Q), down from 424.93 million at Dec 31, 2025. It is the only class of stock.)407.51–––Yes
Holders of 5% or more
Zoetis holders of 5% or more, from the proxy statement or later Schedule 13G filings; each row shows its own date
HolderSharesVotesAs ofSourceNote
The Vanguard Group11.4%–Jan 7, 2026S18Proxy figure from a Schedule 13G/A filed Jan 7, 2026 (47,778,909 shares at Dec 31, 2025).
BlackRock, Inc.8.7%–Jan 26, 2024S18Proxy figure from a Schedule 13G/A filed Jan 26, 2024 (36,492,748 shares at Dec 31, 2023), an older filing than Vanguard's.

From the company's proxy statement (DEF 14A), later Schedule 13G filings and the share counts on its latest annual or quarterly report. Each holder row shows the date of its own filing.

Learn: How to read a proxy statement (DEF 14A): Nvidia's 2026 proxy · Form 4 insider filings: who files, the codes and the footnotes

21What it does with profit

21What it does with profit

What does Zoetis do with its profit?

Dividends declared per share rose from $1.08 (rounded from $1.075) in FY2021 to $2.03 in FY2025, and were $1.06 for the first nine months of FY2026. $770 million was left at Sep 30, 2026 under the $6 billion buyback program authorized in Aug 2024.

Dividend per share

$2.03FY2025

Dividend paid for each share, by financial year.

$ per share

See the numbers
Dividend per share ($ per share)
YearDividend per shareShare of profit paid out
FY2021$1.08–
FY2022$1.35–
FY2023$1.56–
FY2024$1.80–
FY2025$2.03–
  • Buyback · Dec 31, 2021

    Spent $743 million buying back its own shares in FY2021.

    $743M

  • Buyback · Dec 31, 2022

    Spent $1.59 billion buying back its own shares in FY2022.

    $1.6B

  • Buyback · Dec 31, 2023

    Spent $1.09 billion buying back its own shares in FY2023.

    $1.1B

  • Buyback · Dec 31, 2024

    Spent $1.86 billion buying back its own shares in FY2024.

    $1.9B

  • Buyback · Dec 31, 2025

    Spent $3.24 billion buying back its own shares in FY2025, partly with money from the December 2025 convertible notes.

    $3.2B

  • Buyback · Sep 30, 2026

    Bought back 17.7 million shares for $1.66 billion in the first nine months of FY2026.

    $1.7B

22Governance signals

22Governance signals

What do Zoetis' governance filings show?

Auditor
KPMG LLP, since 2011
Auditor changes
None in the period covered
Audit qualifications
None reported
Related-party dealings
The 2026 proxy statement says there were no related person transactions in FY2025 that SEC rules require it to disclose. The board's Corporate Governance Committee reviews any such deal above $120,000.
Credit rating
Moody's and S&P Global Ratings (as stated in the Q3 FY2026 10-Q) A3 (Moody's) / BBB+ (S&P); short-term P-2 / A-2 (outlook Stable), Nov 5, 2026

A credit rating describes the company's ability to repay debt. It is not a rating of the share.

Flags to know about

  • other · Nov 5, 2026

    Securities class action

    City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc. was filed on May 27, 2026 in the Southern District of New York, with an amended complaint on Oct 23, 2026. It alleges misleading statements about demand for and the competitive position of Librela, Simparica Trio, Apoquel and Cytopoint, for buyers from Jan 14, 2025 to May 6, 2026. Zoetis says it has substantial defenses; related shareholder derivative suits were filed in June 2026.

  • other · Nov 5, 2026

    Change of Chief Financial Officer

    The Q3 FY2026 10-Q refers to the transition of the Chief Financial Officer in August 2026; from Aug 17, 2026 the CEO is the officer who reviews segment results.

  • other

    Brazil environmental case

    Since February 2012 the municipality of Ulianopolis, Brazil has pursued a complaint against a Zoetis entity and five other companies. It alleges that waste sent to a local incinerator caused environmental damage needing cleanup; the incinerator lost its permit before destroying the waste. In its FY2025 10-K (Feb 12, 2026), Zoetis said it does not believe its legal matters will have a material adverse effect on its financial position.

23How it got here

23How it got here

How did Zoetis get here?

  1. 2012

    Milestone

    Split from Pfizer

    Zoetis was incorporated in Delaware in July 2012; before that it was a business unit of Pfizer.

  2. 2013

    Milestone

    Listed on the NYSE

    Shares began trading on the NYSE as ZTS on Feb 1, 2013; there was no public market before.

  3. 2020

    Milestone

    Kristin Peck becomes CEO

    Peck took over as CEO in Jan 2020.

  4. 2023

    Business-model change

    Pet insurance stake sold, PetMedix bought

    Zoetis sold a majority of Pumpkin pet insurance for a $101 million gain and bought all of PetMedix, a UK research-stage company that develops antibody treatments for pets, for $111 million upfront in cash; Librela won US approval the same year.

  5. 2024

    Business-model change

    Medicated feed additives sold

    On Oct 31, 2024 Zoetis sold its medicated feed additive products to Phibro Animal Health for a net $299 million; that category was $293 million of FY2024 revenue.

  6. 2025

    Milestone

    Convertible notes fund a buyback

    In December 2025 Zoetis sold $2.0 billion of 0.25% convertible notes due 2029 and used most of the money to buy back shares.

  7. 2026

    Milestone

    Non-US results no longer a month behind

    From Jan 1, 2026 non-US subsidiaries close their books on Dec 31, like the US, instead of a month earlier; 2025 quarters were recast. Sales pulled into Q4 FY2025 lifted International revenue by about 2.5% to 3.5%.

  8. 2026

    Crisis

    Guidance cut and class action

    Zoetis lowered its FY2026 revenue guidance in May and again in August 2026, and a securities class action was filed against it on May 27, 2026.

24Sources and changes

Where every number on this page comes from

Sources (21 documents)
  1. S1Form 10-Q for Q3 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Nov 5, 2026
  2. S2Form 10-Q for Q2 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Aug 6, 2026
  3. S3Form 10-Q for Q1 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · May 7, 2026
  4. S4Form 10-K for FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Feb 12, 2026
  5. S5Form 10-Q for Q3 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Nov 4, 2025
  6. S6Form 10-K for FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Feb 13, 2025
  7. S7Form 10-Q for Q3 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Nov 4, 2024
  8. S8Form 10-Q for Q2 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Aug 6, 2024
  9. S9Form 10-Q for Q1 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · May 2, 2024
  10. S10Form 10-K for FY2023 · SEC EDGAR · Tier 1: company or exchange filing · Feb 13, 2024
  11. S11Form 10-K for FY2022 · SEC EDGAR · Tier 1: company or exchange filing · Feb 14, 2023
  12. S12Form 10-K for FY2021 · SEC EDGAR · Tier 1: company or exchange filing · Feb 15, 2022
  13. S13Zoetis Q3 FY2026 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Nov 5, 2026
  14. S14Zoetis Q2 FY2026 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Aug 6, 2026
  15. S15Zoetis Q1 FY2026 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · May 7, 2026
  16. S16Zoetis Q4 FY2025 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 12, 2026
  17. S17Zoetis Q4 FY2024 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 13, 2025
  18. S18Zoetis 2026 proxy statement (DEF 14A) · SEC EDGAR · Tier 1: company or exchange filing · Apr 8, 2026
  19. S19Zoetis 8-K: convertible senior notes and capped calls (Dec 18, 2025) · SEC EDGAR · Tier 1: company or exchange filing · Dec 18, 2025
  20. S20Zoetis 8-K: senior notes issue and redemption (Aug 27, 2025) · SEC EDGAR · Tier 1: company or exchange filing · Aug 27, 2025
  21. S22Zoetis Q3 FY2025 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Nov 4, 2025
Changes to this page (v1 · Nov 20, 2026)
  1. v1 · Nov 20, 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.

Read the positions policy
Read the full disclaimer

Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.

All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.